An Abbreviated Dual Antiplatelet Regimen Is Also Safe in Patients at High Risk for Bleeding Undergoing Complex Angioplasty

The MASTER DAPT study analyzed the results of an abbreviated (mean 34 days) vs. conventional dual antiplatelet therapy (DAPT) in 4579 patients treated with angioplasty and a biodegradable polymer sirolimus-eluting stent.

Un régimen abreviado de doble antiagregación es también seguro en pacientes con alto riesgo de sangrado que reciben angioplastias complejas

This recent publication on the same study analyzed the evolution within the same strategies of the subgroup of patients with complex angioplasty and compared it with the subgroup of non-complex angioplasty.

“Complex” was defined as any angioplasty procedure done in the three major epicardial vessels, chronic occlusions, stent over 60 mm, more than three stents, bifurcation lesions, or treatment of more than three lesions.

As in the global study, researchers analyzed overall adverse events (NACE; a composite of overall mortality, infarction, stroke, or BARC 3 or 5 bleeding) and ischemic events (MACCE; overall mortality, infarction, or stroke), in both groups, using noninferiority criteria; bleeding events (BARC 2, 3, or 5 bleeding) were analyzed using superiority criteria.

NACE and MACCE were similar between the abbreviated vs. conventional DAPT regimes in patients who underwent complex angioplasty (hazard ratio [HR]: 1.03, 95% confidence interval [CI]: 0.69-1.52, and HR: 1.24, 95% CI: 0.79-1.92, respectively) and non-complex angioplasty (HR: 0.90, 95% CI: 0.71-1.15, and HR: 0.91, 95% CI: 0.69-1.21; p interaction = 0.60 and 0.26, respectively). BARC type 2, 3, or 5 bleeding decreased with abbreviated DAPT in both subgroups (complex and non-complex angioplasty) (HR: 0.64; 95% CI: 0.42-0.98, and HR: 0.70; 95% CI: 0.55- 0.89; p interaction = 0.72).

Read also: ESC 2021 | MASTER DAPT: Dual Antiplatelet Therapy After Coronary Angioplasty in Patients at High Bleeding Risk.

The authors conclude that only one month of DAPT in this group of patients treated with Ultimaster/Tansei stents does not increase the incidence of total adverse events or ischemic events, and it decreases bleeding events independently of angioplasty complexity.

Dr. José Álvarez.
Web Area Director and Editorial Board of SOLACI.org.

Original Title: Duration of antiplatelet therapy after complex percutaneous coronary intervention in patients at high bleeding risk: a MASTER DAPT trial sub-analysis. 

Reference: European Heart Journal (2022) 00, 1–15 https://doi.org/10.1093/eurheartj/ehac284. 


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

Coronary Artery Disease in Aortic Stenosis: CABG + SAVR vs. TAVR + PCI: Data from Spanish Centers

Multiple randomized studies have shown comparable or superior efficacy of transcatheter aortic valve replacement (TAVR) vs. coronary artery bypass graft (CABG).  However, many of...

Evolution of Small Balloon-Expandable Valves

Small aortic rings (20 mm) have posed a significant challenge for both surgery and transcatheter aortic valve implantation (TAVI) due to their association with an...

TCT 2024 | FAVOR III EUROPA

The study FAVOR III EUROPA, a randomized trial, included 2,000 patients with chronic coronary syndrome, or stabilized acute coronary syndrome, and intermediate lesions. 1,008...

TCT 2024 – ECLIPSE: Randomized Study of Orbital Atherectomy vs Conventional PCI in Severely Calcified Lesions

Coronary calcification is associated with stent under-expansion and increased risk of both early and late adverse events. Atherectomy is an essential tool for uncrossable...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Severe Tricuspid Regurgitation: Surgical vs. Transcatheter Edge-to-Edge Repair

While highly prevalent, tricuspid regurgitation is a notably undertreated valvulopathy. Its progression has been associated with higher mortality and significant disability. According to the...

ACCESS-TAVI: Comparing Post TAVR Vascular Closure Devices

Transcatheter aortic valve replacement (TAVR) is a well-established option to treat elderly patients with severe symptomatic aortic valve stenosis. Technical advances and device development...

Endovascular Treatment of Iliofemoral Disease for the Improvement of Heart Failure with Preserved Ejection Fraction

Peripheral artery disease (PAD) is a significant risk factor in the development of difficult-to-treat conditions, such as heart failure with preserved ejection fraction (HFpEF)....